… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration … directed to up to five targets u sing ProQR’s proprietary Axiomer ® RNA editing platform ProQR to receive $ 5 0 million …
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 LEIDEN, … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today announced a …
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora
… ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event Initial … during which the Company will showcase its proprietary Axiomer RNA-editing technology platform, detail the pipeline, …
… ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and … and Clinical Date: November 18, 2022 at 2:30pm CET About Axiomer ® Technology ProQR is pioneering a next-generation …
… ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and … and Clinical Date: May 11, 2022 at 11:15am EDT About Axiomer ® Technology ProQR is pioneering a next-generation …
… ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, … a key patent for its ADAR-mediated RNA editing platform Axiomer®. The oppositions were filed in February 2021 with …